Tag: stage

HOUSTON, July 07, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, is pleased to invite investors to a webinar on July 10, 2025, at 4:15 p.m. ET.

PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’),  a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced two important developments that aim to reinforce the global positioning of potential first-in-class radioenhancer JNJ-1900 (NBTXR3), which is licensed by Janssen Pharmaceutica NV, a Johnson & Johnson company.

CALGARY, Alberta, July 07, 2025 (GLOBE NEWSWIRE) -- shQUAQUash Energy Limited Partnership, an entity created by the member communities of the Nlaka’pamux Nation Tribal Council (NNTC), and BluEarth Renewables (BluEarth) announced today that the quA-ymn Solar Project is now fully operational. The project achieved its commercial operations date (COD) on June 19, on schedule and within budget.

Dr. Anosh Ahmed expands U.S. and international COVID testing contracts with focus on compliance, fraud prevention, and trusted public health services

Electromagnetic Geoservices ASA (the “Company” or “EMGS”) releases information on vessel activity and multi-client sales during the quarter approximately 4-5 working days after the close of each quarter. The Company defines vessel utilisation as the percentage of the vessel charter period spent on proprietary or multi-client data acquisition. Downtime (technical or maritime), mobilisation, steaming, and some standby activities are not included in the utilisation rate.  

At the end of the second quarter 2025 the Company had one vessel on charter, the Atlantic Guardian. The Atlantic Guardian completed the second of two proprietary surveys in India in the quarter and started transit back to Norway for three fully prefunded multi-client surveys in the North Sea with a total contract value of USD 2.7 million.

Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved

Highland, Indiana, July 07, 2025 (GLOBE NEWSWIRE) -- REsimpli, a leading all-in-one AI CRM for Real Estate Investors, is thrilled to announce the launch of its REsimpli 5.0 release that introduces 8 powerful AI Agent tools and a List Pulling Feature that help investors pull off-market properties with necessary filters for the best results. These tools are designed to automate communication, reduce response times, and dramatically improve conversion rates.